Hematopoietic Stem Cell Transplantation

Maedler-Kron, Chelsea; Marcus, Victoria; Michel, René P.

doi:10.1007/978-3-319-29683-8_10

Cited by 11 publications

(9 citation statements)

References 215 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Within squamous epithelium, apoptotic bodies mainly manifest as individual small cells with hypereosinophilic cytoplasm and a condensed nucleus (Figure 1, B). 12 Apoptotic bodies are usually found in the regenerative epithelial compartment such as the basal layer of esophageal mucosa, the neck region of gastric mucosa, and the deeper portion of the crypts in small and large intestinal mucosa. [13][14][15][16] Isolated apoptotic bodies within the surface epithelium of the colon, however, are not diagnostic of GVHD and should be disregarded as they may result from bowel preparative regimens 15,17 or from physiological cell turnover.…”

Section: Graft-versus-host Diseasementioning

confidence: 99%

Pathology of Gastrointestinal and Liver Complications of Hematopoietic Stem Cell Transplantation

Mourad

Michel

Marcus

2019

Archives of Pathology &Amp; Laboratory Medicine

Self Cite

View full text Add to dashboard Cite

Context.— Despite advances in therapeutic and preventive measures, hematopoietic stem cell transplant recipients remain at risk for a variety of gastrointestinal and liver complications. Objective.— To detail the pathologic features of the various gastrointestinal and liver complications occurring after hematopoietic stem cell transplantation in relation to their clinical context. The specific complications covered include graft-versus-host disease, mycophenolate mofetil–induced injury, timeline of infections, neutropenic enterocolitis, gastrointestinal thrombotic microangiopathy, sinusoidal obstruction syndrome, hepatic iron overload, and the controversy around cord colitis syndrome. Data Sources.— The content of this article is based on pertinent peer-reviewed articles in PubMed, relevant textbooks, and on the authors' personal experiences. Conclusions.— The final histopathologic diagnosis requires the integration of clinical and histologic findings and the exclusion of other competing causes of injury. Review of the clinical data, including the original disease pretransplant, the type of transplant, the timing of the gastrointestinal and/or liver manifestations, the timing of the biopsy after transplant, the presence of graft-versus-host disease in other organs and sites, the list of drug regimens, and the clinical and laboratory evidence of infection, is the key to reaching the proper histologic diagnosis.

show abstract

Section: Graft-versus-host Diseasementioning

confidence: 99%

Pathology of Gastrointestinal and Liver Complications of Hematopoietic Stem Cell Transplantation

Mourad

Michel

Marcus

2019

Archives of Pathology &Amp; Laboratory Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Allogeneic stem cell transplant (alloSCT) is a well-established, potentially curative treatment modality for various malignant and non-malignant hematological diseases in which a patient’s diseased blood-producing system is replaced by that of a healthy person [ 1 ]. These patients’ complex care needs demand innovation in care delivery [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

“…Medication adherence is vital regarding clinical outcomes in patients following alloSCT [ 6 , 7 ]: as many as 80% of alloSCT patients develop an acute or chronic Graft-versus-Host Disease (GvHD) [ 8 , 9 ], a serious complication in which the donor’s immune cells attack the recipient’s body [ 1 ] leading to increased morbidity and mortality [ 8 – 11 ]. Although there is limited evidence and the few existing studies did not distinguish between the three medication adherence phases (initiation, implementation, persistence), we found medication adherence to immunosuppressants in alloSCT essential to prevent or treat complications such as acute and chronic GvHD [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Theory-driven development of a medication adherence intervention delivered by eHealth and transplant team in allogeneic stem cell transplantation: the SMILe implementation science project

Ribaut

Leppla

Teynor

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

Background: Medication adherence to immunosuppressants in allogeneic stem cell transplantation (alloSCT) is essential to achieve favorable clinical outcomes (e.g. control of Graft-versus-Host Disease). Over 600 apps supporting medication adherence exist, yet they lack successful implementation and sustainable use likely because of lack of end-user involvement and theoretical underpinnings in their development and insufficient attention to implementation methods to support their use in real-life settings. Medication adherence has three phases: initiation, implementation and persistence. We report the theory-driven development of an intervention module to support medication adherence (implementation and persistence phase) in alloSCT outpatients as a first step for future digitization and implementation in clinical setting within the SMILe project (Development, implementation and testing of an integrated care model in allogeneic SteM cell transplantatIon faciLitated by eHealth). Methods: We applied Michie's Behavior Change Wheel (BCW) and the Capability-Opportunity-Motivation and Behavior (COM-B) model using three suggested stages followed by one stage added by our team regarding preparation for digitization of the intervention: (I) Defining the problem in behavioral terms; (II) Identifying intervention options; (III) Identifying content and implementation options; (IV) SMILe Care Model Prototype Development. Scientific evidence, data from a contextual analysis and patients'/caregivers' and clinical experts' inputs were compiled to work through these steps.

show abstract

“…Allogeneic stem cell transplant (alloSCT) is a wellestablished, potentially curative treatment modality for various malignant and non-malignant hematological diseases in which a patient's diseased blood-producing system is replaced by that of a healthy person [1]. These patients' complex care needs demand innovation in care delivery [2].…”

Section: Introductionmentioning

confidence: 99%

“…Medication adherence is vital regarding clinical outcomes in patients following alloSCT [6,7]: as many as 80% of alloSCT patients develop an acute or chronic Graft-versus-Host Disease (GvHD) [8,9], a serious complication in which the donor's immune cells attack the recipient's body [1] leading to increased morbidity and mortality [8][9][10][11]. Although there is limited evidence and the few existing studies did not distinguish between the three medication adherence phases (initiation, implementation, persistence), we found medication adherence to immunosuppressants in alloSCT essential to prevent or treat complications such as acute and chronic GvHD [12,13].…”

Section: Introductionmentioning

confidence: 99%

Gender Differences in Adherence to Nonpharmacologic Recommendations after Heart Transplant: A Secondary Analysis from the International BRIGHT Study

Trammell¹,

Epstein²,

Liu

et al. 2020

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Hematopoietic Stem Cell Transplantation

Cited by 11 publications

References 215 publications

Pathology of Gastrointestinal and Liver Complications of Hematopoietic Stem Cell Transplantation

Pathology of Gastrointestinal and Liver Complications of Hematopoietic Stem Cell Transplantation

Theory-driven development of a medication adherence intervention delivered by eHealth and transplant team in allogeneic stem cell transplantation: the SMILe implementation science project

Gender Differences in Adherence to Nonpharmacologic Recommendations after Heart Transplant: A Secondary Analysis from the International BRIGHT Study

Contact Info

Product

Resources

About